Research Focus

The Davila Lab aims to understand the cellular and molecular signals that promote the generation of potent and long-lasting tumor-specific T cell responses. Early preclinical studies demonstrated that formulating vaccines to include toll like receptor agonists together with peptides representing tumor antigens induced potent CD8 cytotoxic T cell responses and were effective at treating tumors in a prophylactic and therapeutic setting. We continue to exploit the T cell’s ability to recognize and destroy tumors.

Selected Publications

Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Davila E. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 2015 Mar 20;PubMed PMID: 25795705.

Kaczanowska S, Joseph AM, Guo J, Tsai AK, Lasola JJ, Younger K, Zhang Y, Gonzales CV, Davila E.A Synthetic CD8α:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Res. 2017 Dec 15;77(24):7049-7058.

Jitao Guo1, Elena Muse1, Allison J. Christians1, Steven J. Swanson2, and Eduardo Davila1, 3, 4  Using an anticancer drug cocktail of MK2206, Nut7441, and tramatenib to improve dendritic cell-based cancer vaccines. Cancer Immunol Res. Accepted May 2019


Lab Personnel

Eduardo Davila, PhD 
Principal Investigator

Breelyn Wilky, MD
Associate Professor
Associate Member

Yupanqui Caldas, PhD
Senior PRA

Jiangli Chen, PhD
Senior PRA

Allison Christians, BA
Professional Research Assistant

Degui Geng, PhD
Assistant Research Professor

Jitao Guo, PhD
Assistant Research Professor

Jing Liu, PhD
Visiting Postdoctoral Fellow

Joseph Magno, BA
Professional Research Assistant

Kyle Powers, BS
Professional Research Assistant

Amelia Sanchez, BS
Professional Research Assistant